Alectinib remains the standard of care in this setting, but where unavailable, the findings provide evidence against adjuvant crizotinib.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/crizotinib-not-beneficial-resected-early-alk-nsclc-2025a1000nxr?src=rss
Author :
Publish date : 2025-09-10 14:04:00
Copyright for syndicated content belongs to the linked Source.